Abstract: Classical ETV-resistance mutations rtT184/S202/M250substitution+rtM204V/I+-L180M (LAM-r), rtA186T, and rtI163V were detected in 1252 (5.69%), 14 (0.06%), and 230 (1.05%) of the 22,009 patients, respectively.
Abstract: Compared to wild-type strain, two patient-derived mutants' rtL180M+A186T+M204V and rtL180M+T184S+A186T+M204V had 86.7% and 89.2% decreased replication capacity, 210
CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.
PMID: 30670420
2019
Antimicrobial agents and chemotherapy
Abstract: CMCdG also reduced the level of HBVETV-R L180M/S202G/M204V viremia by ~1 log in HBVETV-R L180M/S202G/M204V-infected human liver-chimeric mice, while ETV (1 mg/kg/day q.d.) completely failed to reduce the viremia.
Abstract: CMCdG potently inhibited HBV production in HepG2.2.15 cells (50% inhibitory concentration [IC50], ~30 nM) and HBVWT Ce plasmid-transfected Huh7 cells (IC50, 206 nM) and efficiently suppressed ETV-resistant HBVETV-R L180M/S202G/M204V (IC50, 2,657 nM), while it showed no or little cytotoxicity (50% cytotoxic concentration, >500 muM in most hepatocytic cells examined).
Abstract: CMCdG's in vitro activity was determined using quantitative PCR a
Synthesis of an Anti-hepatitis B Agent, 2'-Fluoro-6'-methylene-carbocyclic Adenosine (FMCA) and Its Phosphoramidate (FMCAP).
PMID: 30589264
2019
The Journal of organic chemistry
Abstract: 2'-Fluoro-6'-methylene-carbocyclic adenosine (FMCA, 12) and its phosphoramidate prodrug (FMCAP, 14) have been proven as a potential anti-HBV agent against both adefovir-resistant as well as lamivudine-resistant double (rtL180M/rtM204V) mutants.
Abstract: Furthermore, in vitro, these agents have demonstrated significant activity against lamivudine/entecavir triple mutants (L180M + S202G + M204V).
Prevalence of Hepatitis B Virus Infection in Shenzhen, China, 2015-2018.
Abstract: NAs resistant mutation occurrence patterns were multitudinous; single mutation patterns of rtM204I/V and rtL180M occurrences accounted for majority, followed by the combinational mutation pattern L180M + M204I/V.
Introduction: A total of 8 HBV classical mutation sites are conventionally tested for HBV patients in most clinical labs, including M204I/V, L180M, T184A/F/I/L/S, L181T/V, M250I/L/V, M236T, S202G, and V207I.
Result:
Mutations in reverse transcriptase region of HBV affect Hepatitis B surface antigen titers and its correlation with HBV DNA.
PMID: 32087080
2019
Journal of infection in developing countries
Abstract: HBsAg was positively correlated with HBV DNA levels in the wild-type group (r = 0.322, p < 0.01), as well as in the M204I/V, L180M+M204I/V, A181T/V, and N236T subgroups, while no correlation was found in the A181T/V+N236T subgroup (r = 0.159, p = 0.217).
Abstract: RESULTS: HBsAg was lower in the wild-type and A181T/V+N236T groups as compared to the M204I/V, L180M+M204I/V and N236T groups.
Abstract: Then, the
Molecular Epidemiology of Hepatitis B Virus in Turkish Cypriot.
PMID: 31880889
2019
Polish journal of microbiology
Table: L180M
Discussion: When analyzed in greater details, rtM204I, rtI233V, rtL80I, and rtL180M mutations were not detected before, and these mutations, particularly rtL80I and rtL180M, restore the activity of viral polymerase to near wild type levels, which helps to promote the replication of mutants.
Evaluation of the pol/S Gene Overlapping Mutations in Chronic Hepatitis B Patients in Northern Cyprus.
PMID: 31880877
2019
Polish journal of microbiology
Discussion: LAM-associated resistance triple mutation pattern (rtV173L + rtL180M + rtM204V) has also been shown to enhance viral replication compared with rtL180M + rtM204V.
[Identification and molecular-genetic characteristics of the hepatitis B virus among HIV-infected patients in Arkhangelsk.]
Abstract: Two HBV isolates with drug resistance mutations in the polymerase gene, leaded to amino acid substitutions (L180M, M204V) associated with the resistance development to lamivudine, entecavir, telbivudine and tenofovir were identifying.
High frequency of drug resistance mutations in the HBV genome in ART-experienced HIV-coinfected patients in southwestern Nigeria.
HBV mutation literature information.
PMID: 
2019
Emerging microbes & infections
Browser Board
Co-occurred Entities
Filtrator
ViMRT